About Mitral Valve
The mitral valve manages blood flow from the left atrium to the left ventricle. The valve prevents the backward flow of the blood. Mitral regurgitation is a common mitral valve disorder that causes the abnormal backward flow of the blood. Cardiologists use mitral surgical valve repair procedures or transcatheter replacement procedures to treat this disorder. About 80,000 individuals undergo these two procedures for treating the disorder.
Technavio’s analysts forecast the global transcatheter mitral valve replacement market to grow at a CAGR of 21.93% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global transcatheter mitral valve replacement market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of transcatheter mitral valve implants.The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Transcatheter Mitral Valve Replacement Market 2016-2020
Technavio recognizes the following companies as the key players in the global transcatheter mitral valve replacement market: Abbott Laboratories, Edwards Lifesciences, Micro Interventional Devices, and Neovasc.
Other Prominent Vendors in the market are MitrAssist, NaviGate Cardiac Structures, and Valtech.
Commenting on the report, an analyst from Technavio’s team said that the development of novel products will promote growth for this market. Advances in technology, material, and design of prosthetic valves and delivery devices have led surgeons to perform mitral valve replacement procedures with better post-surgical outcomes. The growing focus on compatibility and durability of implants in the human body led cardiologists to prefer transcatheter mitral valves to mechanical prosthetic valves. The shift from open-heart procedures to minimally invasive methods for the implantation of devices since 2005 has been a breakthrough in the demand and sales of heart valves.
According to the report, prevalence of mitral regurgitation is one of the drivers that led to the growth of this market. Mitral regurgitation is a common heart valve disorder that affects 2%-3% of the population worldwide. The disorder is becoming prevalent among all age groups rapidly. About 0.5% of individuals aged 18-45 and 9% of people aged 60-75 have this disorder. In 2009, research studies estimated that more than 176 million people worldwide have the disorder. These studies also estimated that more than four million individuals in the US had mitral regurgitation. Of this number, about one in 10 individuals was aged 75 and above.
Further, the report states that availability of alternative treatment is negatively affecting the sales of transcatheter mitral valve implants. Transcatheter mitral valve replacement is a minimally invasive surgical procedure. This procedure has been proven to be safe and efficient, improving the quality of life. However, mitral valve repair surgical procedures are medical consultants' first choice for treating mitral regurgitation. Mitral valve repair surgery involves the implantation of a stent-like device for reshaping the posterior region of the annulus to repair the damaged mitral valve. The surgical procedure offers better postoperative left ventricular function, lowers long-term morbidity, and increases life expectancy compared to transcatheter mitral valve replacement procedure. Cardiac Dimensions' Carillon and Edwards Lifesciences' Monarc are two major mitral valve repair devices available in the market. These devices are less expensive compared to transcatheter mitral valve replacement devices.
Abbott Laboratories, Edwards Lifesciences, Micro Interventional Devices, Neovasc, MitrAssist, NaviGate Cardiac Structures, Valtech.